EMA Approval: Lenacapavir (Sunlenca), a First-In-Class HIV Capsid Inhibitor

In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.

This Premium deep dive into Sunlenca includes:

  • the industry context
  • the clinical data
  • the target rationale
  • the mechanism of action
  • the drug’s origins
lenacapavir (Sunlenca), HIV capsid inhibitor, Twice yearly injection after a 2-week oral loading, For adults with multidrug-resistant HIV-1 infection, Gilead Sciences
Lenacapavir (Sunlenca), chemical structure

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.

Join Subscribers from

…and hundreds more!